Brief: Cel-Sci Corp Files For Offering Of 6 Million Shares Of Common Stock- SEC Filing
Brief: Cel-Sci Corporation Announces Pricing Of Public Offering
Brief: CEL-SCI Enters Strategic Agreement With Amarox For The Registration, Commercialization, And Distribution Of Multikine In Saudi Arabia
Drug developer CEL-SCI dives on deep-discounted equity raise
Drug developer CEL-SCI plunges after unveiling stock offering
Brief: CEL-SCI Announces Proposed Public Offering
Brief: Cel-Sci Announces Pricing Of $5.7 Million Offering
Brief: CEL-SCI Corp Files For Mixed Shelf Offering Of Up To $100 Million
Brief: Cel-Sci Says Prices Public Offering Of 2 Million Shares At $2.50 Per Share
Brief: CEL-SCI Corp To File For Regulatory Approval Of Multikine In Saudi Arabia
Brief: CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
Brief: CEL-SCI announces closing of $2.5 million offering
Brief: CEL-SCI To Initiate Multikine Confirmatory Phase 3 Cancer Trial
Brief: CEL-SCI Announces Closing Of $5 Million Offering
Brief: CEL-SCI Announces Proposed Public Offering Of Common Stock
Celsius founder Alex Mashinsky pleads guilty to fraud charges (updated)
Brief: Cel-Sci Corp Says On November 13, Patricia B Prichep Has Assumed The Duties Of Chief Financial And Operations Officer
Brief: US FDA And CEL-SCI Agree On Use Of PD-L1 Biomarker
Brief: CEL-SCI Provides Phase 3 Population Analysis Results For Multikine